The down-regulation of FHL1, which specifically combined to the activation function domain-1 of oestrogen receptor (ER) involving in the development and progression of breast cancer, caused ER to be recruited to an estrogen-responsive promoter and bind to an estrogen-responsive element and repressed the transcription and translation of estrogen-responsive genes [43, 44]. The gene discussed is FHL1; the disease is breast cancer.